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Hepatoblastoma (HB), despite being rare, is the most common malignant hepatic tumour in children. It is debatable whether 
adult HB occurs as an entity. Several features of the 
tumours described in adults are strikingly different 
from HB in the paediatric age group.1
In the February 2015 issue of SQUMJ, Rabah et al. 
described Oman’s experience of HB over the last 21 
years.2 HB is extremely rare in adults aged between 
19 and 84 years, with only 40 reported cases of adult 
HB from 1958 to 2013.3,4 It is presumed that the 
majority of adult HB cases are, in fact, misdiagnosed 
hepatocellular carcinoma (HCC), combined HCC-
cholangiocarcinoma or carcinosarcoma.5 
Adult HB usually presents with abdominal pain, 
weight loss and a palpable liver mass on physical 
examination. Similarly, Rabah et al. found that the 
main symptom in the Omani children with HB was 
a palpable mass in the abdomen.2 HB affects both 
hepatic lobes and commonly presents as a unifocal 
large mass ranging from 5–25 cm.3,4 
According to Rougemont et al., liver fibrosis or 
cirrhosis was diagnosed in 30% of reported adult HB 
cases, in contrast to paediatric HB which appeared 
nearly always in children with no primary hepatic 
disease.1 The main differential diagnosis of adult HB 
is HCC.1 Unfortunately, there are no typical features 
of HB that are visible on ultrasound, computed 
tomography (CT) or magnetic resonance imaging 
(MRI) of the liver. Kishimoto et al. suggested that 
intramural classification is helpful in the diagnosis of 
HB.6 Other radiological features suggestive of HB are 
hypervascularity and cystic changes. However, none 
of the previously mentioned radiological features are 
specific for HB and all of these radiological features 
can be found in all types of liver tumours. 
Postoperative pathological examination is the 
gold standard for diagnosing HB. HB and HCC 
usually display remarkable gross, histological and 
immunohistochemistry similarities.1,6 In addition, 
mixed features of HB and HCC can coexist in one 
tumour,7 and successive occurrence of HB and HCC 
in the same patient has been described.8,9 The use of 
chemotherapy in HB may lead to architectural and 
cytological changes resembling HCC.10 Another 
differential diagnosis of HB in an adult would be 
the coexistence of hepatocellular-cholangiocarcinoma 
with stem cell characteristics. Ishak et al. proposed a 
histological classification that classifies HB into epithelial 
and mixed epithelial types, which are most common, and 
the mesenchymal type, which is less common.11 
Molecular progress has enabled the recognition of 
different gene expression patterns in liver tumours.12 
Molecular overlap and coexistence of HB and HCC in 
adult cases support the hypothesis that these tumours 
may originate from a common progenitor cell.12
Surgical resection, if feasible, remains the 
main method of HB management. Neoadjuvant 
chemotherapy has been used to shrink the tumour, 
prevent intraoperative blood loss and delineate 
the tumour from the surrounding tissue, therefore 
facilitating easy resection.13 Rabah et al. used three 
to four cycles of neoadjuvant chemotherapy in their 
study, followed by surgical resection in patients with 
Pretreatment Extent of Disease stage II, III and IV 
who were deemed to have resectable disease.2
Postoperative chemotherapy was also used by 
Rabah et al. as two to five cycles of chemotherapy were 
given to 11 out of 15 patients.2 Other local ablative 
procedures used in the treatment of HCC, such as 
ethanol ablation and radiofrequency ablation (RFA), 
have been tried mainly for the treatment of recurrent 
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tumours post surgical resection.14,15 Randomised trials 
comparing local ablative therapy, such as RFA, versus 
surgical resection for a small tumour of less than 3 cm 
are required to assess the efficacy of such treatments 
in HB. Other methods used in the treatment of 
advanced HCC, such as transarterial chemotherapy 
and transarterial radioembolisation, need to be 
evaluated, especially in adults with advanced HB who 
are not surgical candidates.
Based on paediatric experience, liver transplan-
tation has been associated with marked survival 
improvement, especially in those with an unresectable 
tumour. One of the 15 children described by Rabah 
et al. had a liver transplantation due to multi-lobar 
involvement.2 Generally, the Milan criteria are used to 
assess which patients with HCC are suitable for liver 
transplantation.16 These criteria, which are also valued 
for assessing transplantation in HB patients, need 
further investigation. The survival rate of children who 
receive transplants due to HB is close to 80%. This 
percentage is based on results from the International 
Society of Paediatric Oncology and a review of the 
global experience of HB and liver transplantation.17 
Rabah et al. presented a survival rate of 91% in their 
study, despite many obstacles faced by the treating 
paediatricians.2 This is comparable to other recently 
published studies.18–20
HB prognosis has improved since 1995 and this 
is most likely due to early diagnosis, improvement in 
surgical techniques, postoperative care and the use of 
neo-adjuvant and adjuvant chemotherapy.1,3
In conclusion, the results of Rabah et al.’s study and 
the experience gained over many years should guide 
oncologists in treating patients diagnosed with HB 
and encourage all parents of such paediatric patients 
to address their treatment as soon as possible. In 
addition, the application of paediatric HB protocols in 
the treatment of adult HB may prove beneficial. 
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